Startseite>>Signaling Pathways>> Ubiquitination/ Proteasome>> Proteasome>>Epoxomicin

Epoxomicin (Synonyms: BU 4061T)

Katalog-Nr.GC12494

Epoxomicin is a selective proteasome inhibitor that effectively inhibits the chymotrypsin-like (CH-L) activity of the 20S proteasome, with an IC50 of approximately 40-80nM.

Products are for research use only. Not for human use. We do not sell to patients.

Epoxomicin Chemische Struktur

Cas No.: 134381-21-8

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
337,00 $
Auf Lager
1mg
103,00 $
Auf Lager
5mg
280,00 $
Auf Lager
20mg
855,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com


Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Epoxomicin is a selective proteasome inhibitor that effectively inhibits the chymotrypsin-like (CH-L) activity of the 20S proteasome, with an IC50 of approximately 40-80nM[1]. Epoxomicin covalently binds to the catalytic β subunits LMP 7, X, Z, and MECL 1 of the proteasome, leading to inhibition of the proteasome subunits' CH-L, T-L, and PGPH catalytic activities[2].

In vitro, Epoxomicin shows considerable cytotoxicity against B16-F10, HCT116, Moser, P388, and K562 cells, with IC50 values of 0.002μg/mL, 0.005μg/mL, 0.044μg/mL, 0.002μg/mL, and 0.037μg/mL, respectively[3]. Epoxymycin (0.2 and 2 μM) treated HEK293T cells for 1 hour, inhibiting the expression of proteasome beta-2 and beta-5 subunits in the cells[4]. Epoxomicin (100 nM) for 24 hours in Plasmodium falciparum cells results in a 77% reduction in gametocytes[5].

In vivo, Epoxymycin (0.5mg/kg), administered intraperitoneally, reduced polyubiquitination in GAS muscle of C57BL/6 mice by 23% and increased polyubiquitination in liver by 41%, the latter associated with The inhibitory effect of proteasome β5 is consistent [6]. Epoxymycin (0.5mg/kg/day) was administered to KI and WT mice for 1 week using a subcutaneously implanted osmotic minipump, which reduced the chymotrypsin-like activity of the mice by approximately 50%[7] .

 

References:

[1] Meng L , Mohan R , Kwok B H B ,et al.Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity[J]. Proceedings of the National Academy of Sciences, 1999, 96(18):10403-10408.

[2] Aboulaila M , Nakamura K , Govind Y ,et al.Evaluation of the in vitro growth-inhibitory effect of epoxomicin on Babesia parasites.[J].Veterinary Parasitology, 2010, 167(1):19-27.

[3] Hanada M,  Sugawara K, Kaneta K, et al. Epoxomicin, a new antitumor agent of microbial origin.[J] Antibiot (Tokyo). 1992 Nov;45(11):1746-52.

[4] Fricker L D, Gelman J S, Castro L M, et al. Peptidomic analysis of HEK293T cells: effect of the proteasome inhibitor epoxomicin on intracellular peptides[J]. Journal of proteome research, 2012, 11(3): 1981-1990.

[5] Czesny B , Goshu S , Cook J L ,et al. The Proteasome Inhibitor Epoxomicin Has Potent Gametocytocidal Activity[J]. 2009.

[6]Jamart, Cécile, Gomes A V , Dewey S ,et al. Regulation of ubiquitin-proteasome and autophagy pathways after acute LPS and epoxomicin administration in mice[J].Bmc Musculoskeletal Disorders, 2014, 15(1):166.

[7]Schlossarek,Saskia,Singh,et al. Proteasome inhibition slightly improves cardiac function in mice with hypertrophic cardiomyopathy[J].Frontiers in Physiology, 2014.

Bewertungen

Review for Epoxomicin

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Epoxomicin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.